阿尔茨海默病中DNA和RNA的表观遗传修饰
Paula Martinez-Feduchi1, Peng Jin1, Bing Yao1
1Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, United States.
Frontiers in molecular neuroscience
|May 10, 2024
概括
研究阿尔茨海默病 (AD) 的表观遗传机制至关重要. 了解DNA和RNA修饰可以揭示用于诊断和治疗这种常见痴呆症的新生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,既有家族形式,也有零星形式.
- 散发性AD涉及复杂的遗传,表观遗传和环境因素,影响疾病的进展.
- 表观遗传修饰,如DNA和RNA的化学变化,调节基因表达.
研究的目的:
- 探索表观遗传机制在阿尔茨海默病中的作用.
- 为了确定潜在的表观遗传生物标志物用于AD诊断和治疗.
- 了解表观遗传调节如何影响AD病理.
主要方法:
- 关于阿尔茨海默病表观遗传学的当前文献的综述.
- 对研究ADN和RNA修饰的研究进行分析.
- 检查表观遗传变化与神经退行症中的基因表达之间的联系.
主要成果:
- 表观遗传修饰与阿尔茨海默病的发展和进展有关.
- 这些修改可以改变转录和转录后的基因表达水平.
- 特定的表观遗传模式可以作为诊断或预后生物标志物.
结论:
- 表观遗传机制是阿尔茨海默病病理学的关键组成部分.
- 针对表观遗传途径提供了潜在的治疗策略.
- 对AD表观遗传学的进一步研究对于推进诊断和治疗选择至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.通过DNA甲基化.基因组RNA的修改 基因组RNA的改变环绕RNAss 的时间.表观遗传学是指表观遗传学.在 lncRNAs 中.这就是miRNAs.没有编码的RNAs.更多相关视频
08:33Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
7.5K
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
9.6K
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
RNA Editing
9.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.0K
RNA Stability
33.5K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
33.5K
Chromatin Structure Regulates pre-mRNA Processing
7.0K
In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
The chromatin structure, especially...
7.0K
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
